The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | Challenges that exist in bringing CAR T-cell therapy to more patients with R/R lymphoma
In this video, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, highlights logistical challenges persisting in access to CAR T-cell therapy for patients with lymphoma, citing issues with caregiver requirements, payer authorization, and the mandated four-week stay at the treating site. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
